atepeq/tico19 huggingface dataset:
This is one line of scientific research which is currently being pursued to develop safe and effective COVID-19 treatments.
Yennë kɛ̈n töŋ kän ë yɔ̈ɔ̈pë käkë konyë pïr abuɔth cök ëmɛnë ago kë piɛth loi ku yïlany lajik de KOBIT-19.
Other research directions include the development of a COVID-19 vaccine and convalescent plasma transfusion.SARS-CoV-2 has about 66 druggable proteins, each of which has multiple ligand binding sites.
Dhölke yɔ̈ɔ̈p köki anɔŋic cäŋë lɔtueŋë wäl ë KOBIT-19 kuöjɔla toomde riɛm në guɔ̈pic. SARS-CoV-2 anɔŋ kä cït wɛl 66 nɔŋic protin, e tök yic naŋ ligan ku jɔla ɣänmat kuötic.
Analyzing those binding sites provide the reasonable project of developing effective antiviral drug against COVID-19 proteins.
Cɛthë c në ye ɣänmatkä aagɛm ajuɛrë wɛ̈t piɛthë lɔtueŋ ë lajiŋë wɛlë bairäth tënë protin de KOBIT-19.
Of the most important SARS-CoV-2 target proteins are papain-like protease, RNA dependent RNA polymerase, helicase, S protein, and ADP ribophosphatase.
Në kë ye kë tueŋ apɛi tënë SARS-CoV-2 cë täuë kë rilic aaye papen -cït proteth gei de rɔtë RNA, polimereth RNA, proti de heliketh, ku ribopothpateth de ADP.
Hussein A A, et al studied several candidate compounds which then optimized and analyzed for their skeleton similarity with the highest similar approved drugs in order to accelerate a potent anti-SARS-CoV-2 drug development in his preclinical study to be recommended in a clinical study design.
Hussein A A, et al acë kuen në kä juëc wɛ̈r kuɔthïïm gäk apɛi wën lekelaathic ëke cï rok lïr keic në yomkɛn thɔ̈ŋ kekë wɛl cï ke gam nɔŋ thɔ̈ɔ̈ŋ dït ago luoi bën nhial de piathë wɛl ke SARS-CoV-2 juak ë lɔnhial tënë akërnhiaam denë kuën ë göörë cäät në kuë den akïmic.
Chloroquine is an anti-malarial medication that is also used against some auto-immune diseases.
Kolorkuin e wäl ë yïlanyë juäi wɛ̈n e loi bïnë tuɛnytuɛny kök tɔ̈ në guɔ̈pic ya alacu.
On 18 March, the WHO announced that chloroquine and the related hydroxychloroquine would be among the four drugs studied as part of the Solidarity clinical trial.
Ɣɔn e Kol nïn 18, go APMP caal lɔn bïnë kolorkuin ubup ku kolorkuin ë nyin pïu thiäk thookaabë tɔ̈ në walic ke ŋuan gɔ̈ric kë ye baŋde athëëmakïm ë köc atök.
New York governor Andrew Cuomo announced that New York State trials of chloroquine and hydroxychloroquine would begin on 24 March.On 28 March, the FDA authorized the use of hydroxychloroquine sulfate and chloroquine phosphate under an Emergency Use Authorization (EUA).
Hakïm de New York Andrew Cuomo ecë caal lɔn bï athëëm wäläya de New York bïnë ye loi tënë kolorkuin ë ubup ku kolorkuin ë nyin pïu jöök kë Kol e nïn 24. Aköl e Akɔnydït nïn 28, go FDA wäl de kolorkuin thälpet ë nyin pïu ku kolorkuin pothpet ë ubuppäl bec në rinke Teemë thïn Ukbma de Luɔi (TUL)
The treatment has not been approved by the FDA's clinical trials process and is authorized under the EUA only as an experimental treatment for emergency use in patients who are hospitalized but are not able to receive treatment in a clinical trial.
Yïlac aŋot ë kënë guɔ gam në kuɛrka athëëmthëëm de FDA ku aye gam bec në ukuma ë rinke TUL e kë ye nyothde yïlac tënë luɔiden ë rɔt tɛɛm tënɔŋ kɔc tuany cï tääc panakïm kua kën yöök kekë yïlac në thëmdë akïmic
The CDC has said that "the use, dosing, or duration of hydroxychloroquine for prophylaxis or treatment of SARS-CoV-2 infection" are not yet established.
Acï CDC lueel lɔn nɔŋ "luɔide, dëkde, wälë dhamɛnde kolorkuin ë nyin pïu de propelɛdhith wälë yïlanyde wuɔɔk ë SARS-CoV-2" aakënë guɔ cɔ̈k piny.
Doctors have said they are using the drug when "there's no other option".
Dïktoor aacë jam ka loi wäl në "cën en dɛ̈t lɔc".
A Turkish research team in Istanbul is conducting a small study on the use of chloroquine in combination with zinc, vitamin A, vitamin C and vitamin D.
Akuutde Turki ë yɔ̈ɔ̈p tɔ̈ Istanbul aa loi kuën thin kor në lɔŋde luɔi de kolorkuin në mɛ̈ɛ̈t mɛ̈të ke yic kekë dhiŋ, bïtamin A, bïtamin C ku bïtamin D.
Large studies are underway at Duke University and the University of Oxford.
Akuënkuëndït aatɔ̈ dhölic baŋde jamade Duke ku jama de Oxford.
NYU Langone Medical School is conducting a trial on the safety and efficacy of preventative use of hydroxychloroquine.
Thukulde wɛl ë NYU Langone aloi athëm tënë pial ku juëkëic ë gëlë luɔi de kolorkuin ë nyin pïu.
Chinese clinical trials in Wuhan and Shenzhen claimed to show favipiravir was "clearly effective".
Athëëmthëëm akïm ke Caina tɔ̈ Wuhan ku Shenzhen aaye kï lueel bïk nyuɔth pabipirabir e "lui apiɛth".
35 patients in Shenzhen tested negative in a median of 4 days, while the length of illness was 11 days in the 45 patients who did not receive it.
Ayanïïn 35 tɔ̈ Shenzhen cï them ku rɛ̈ɛ̈rkï guupë pɛth në nïn cɛlic ke 4, ke bërëic ë tuany ë nïn 11 të ë ayanïïn ka 45 ë kën e yöök.
In a study conducted in Wuhan on 240 patients with pneumonia, half were given favipiravir and half received umifenovir.
Në cärë cï loi Wuhan tënë ayanïïn ke 240 tënɔŋ tuany alirë piöuic nhuth e cï yiën pabïpirabir ku lööm nhuth në umipenobir.
The Italian Pharmaceutical Agency reminded the public that the existing evidence in support of the drug is scant and preliminary.
Dutunyë ɣön ë wɛl ke Itali e juöör ëbën täknhom lɔn tɔ̈ kë ye wäl kuɔny në nyoth kä lik ku akërnhiaam.
On 2 April, Germany announced that it would purchase the drug from Japan for its stockpile, and use the military to deliver the drug to university hospitals, where the drug will be used to treat COVID-19 patients.
Kë Akɔ̈nydït e nïn 2, go Germany caal lɔn bï kek ɣööc ë wäl tënë Japan në wëukɛn tɔ̈ në tɔ̈uic, ku loi kï jec bï kek wɛl gam panakïm ë jamaic agorë wal lɔ loi bïnë ayanïïn ke KOBIT-19 lɔ alacu.
According to the South China Morning Post, Shinzo Abe has made overtures to the Trump administration about purchasing the drug.The drug may be less effective in severe cases of illness where the virus has already multiplied.
Në të cït të ye Agöt becë nhiäkduur ë Thath Caina e luɛl thïn, Shinzo Ab acë thiëc loi tënë akuma de Trump në baŋde ɣööcë wɛl. wäl alëu bë lui amääth tënë tuany cë nyindït apɛi wɛ̈n cï bairäth ye yic mät thïn apɛi.
It may not be safe for use by pregnant women or those trying to conceive.
Acë lëu bë piath kekë tiŋ liac wälë kɔc wïc bïk yöök ke meth
One study of lopinavir/ritonavir (Kaletra), a combination of the antivirals lopinavir and ritonavir, concluded that "no benefit was observed".
Akuën töŋë lopinabir/ritonabir(kaletra), amɛ̈tëic de wɛlke bairäth ë lopnabir ku ritonabir, ku thiök cök ë "acën kë juɛk thïn e tïŋ".
The drugs were designed to inhibit HIV from replicating by binding to the protease.
Kekë wɛlkäake loi bïk HIV ya gɛ̈l nyin piny në dhiënh en rɔtdhiëëth bï ya matë protethic.
A team of researchers at the University of Colorado are trying to modify the drugs to find a compound that will bind with the protease of SARS-CoV-2.There are criticisms within the scientific community about directing resources to repurposing drugs specifically developed for HIV/AIDS.
Akuut kɔc ë yɔ̈ɔ̈p tɔ̈ jamade Colorado aathem bïk wɛl nyɔkë luɔi agokï kë kuötic yöök bï mat kekë proteth de SARS-CoV-2. Anɔŋ jiëtë cök tënë wunë käke pial baŋde wɛ̈lë käŋ në kanadɛnë luɔi ë cï rok ë juër ë lɔtueŋ wɛ̈nthɛɛr ëke käke HIV/AIDS.
The WHO included lopinavir/ritonavir in the international Solidarity trial.
APMP acë lopinabir/ritonabir matë athëëm ë köc atök në pinynhom.
Remdesivir was created and developed by Gilead Sciences as a treatment for Ebola virus disease and Marburg virus infections . Gilead Sciences subsequently discovered that Remdesivir had antiviral activity in vitro against multiple filo-, pneumo-, paramyxo-, and corona- viruses .
Remdethibir e cak ku loi bë lɔtueŋ në käke pial ë Gilead kë yennë bairäth Ebola alacu ku wuɔ̈kë Marburg bairäth. Käke pial ë Gilead acïk bënë dhiɛl pinyë yöök lɔn ye Remdethibi nɔŋen wal nɔŋ ajɛraat en nɛ̈kë bairäth tɔ̈ në bitroic ë lɔ kekë pilo kuötic-, ku koronabairäth.
One issue with antiviral treatment is the development of resistance through mutations that can lead to more severe disease and transmission.
Töŋ e wɛ̈t apɛi kekë yïlany e loi në wäl ëgël ë bairäth e luɔi de lɔtueŋ ë jïëcde në baŋde tɛ̈ɛ̈këic lëu bë tuany rac apɛi bëi ku wook rɔt.
Some early pretrial studies suggest remdesivir may have a high genetic barrier to resistance.There are several clinical trials underway, including two conducted by Cleveland University Hospitals; one for people with moderate illness and another for those with more severe illness.
Kuën ë dac thëm akërnhiaam kök aye remdethibir thɔ̈ŋkɔu lɔn lëu ben naŋ wuɔ̈c ë jïn tënë jïc. Anɔŋ athëëm akïm kuötic tɔ̈ dhölic, nɔŋ yïk käŋ kerou cï ke loi në Panakïm ë Jama Cleveland; tök kë ye kënë kɔc nɔŋ tuany kor ku dɛ̈t kekë kɔc nɔŋ tuany rilic.
There are three ongoing clinical trials of intravenous vitamin C for people who are hospitalized and severely ill with COVID-19; two placebo controlled (China, Canada) and one with no control (Italy).
Anɔŋ athëëmthëëm kediäk ë Bïtamin C e tuɔm ë guɔ̈pic loi rɔt ëmɛn tënë kɔc cï ke tääc ku a tuany apɛi në KOBIT-19. Ɣän kerou cï ke lëu në titë nyin piny (Caina, Kanada) ku töŋ cën titë nyin piny e (Itali).
New York State began trials for the antibiotic azithromycin on 24 March 2020.
Wäläya de New York acë jɔk athëëm de antïbayotik adhithromycin kë Kol ye nïn 24, 2020
Japan's National Center for Global Health and Medicine (NCGM) is planning a clinical trial for Teijin's Alvesco (ciclesonide), an inhaled corticosteroid for asthma, for the treatment of pre-symptomatic patients infected with the novel coronavirus.
Tëde Pinynhom ë Pial Dït ëbai de Japan ku Wal(TPPW) ajuit athëëm ë kïm de Teijin Albethko(Cikalithonit) e kortiko Itheroid ye miɛt akɛ̈nythïn në wɛ̈t ë adhiäma kë ye yïlany de cït ë tuany tueŋ tënë ayanïïn cë wuɔk në koronabairäth.
A form of angiotensin-converting enzyme 2, a Phase II trial is underway with 200 patients to be recruited from severe, hospitalized cases in Denmark, Germany, and Austria to determine the effectiveness of the treatment.
E kë ye tɔ̈ kë ye aŋiotenthin-ëye noŋ 2 wel, atëk athëëm ë II atɔ̈ dhölic kekë ayanïïn ke 200 bï ke gɔ̈t tënë ayanïïn ril këdɛnic apɛi tɔ̈ Denmak, Gërmani, ku Othtria ago ë piathë yïlac tïŋ të yïnen thïn.
Researchers from the Montreal Heart Institute in Canada are currently studying the role of colchicine in reducing inflammation and pulmonary complications in patients suffering from mild symptoms of COVID-19.
Kɔc yɔ̈ɔ̈p tɔ̈ thukulë piöu de Montriɛl tɔ̈ Kanada atɔ̈ ëmɛn ëke kuen lonë kolcicine në dhukë piny abiör ku riɛlë yic rälë piöu tënë cïtë tuany kor de KOBIT-19.
The study, named COLCORONA, is recruiting 6000 adults aged 40 and over who were diagnosed with COVID-19 and experience mild symptoms not requiring hospitalization.
Akuën cï cäk kë cɔl KOLKORONA , agɔ̈t kɔc dït nɔŋ ruön 40 lɔtueŋ ëke 6000 wɛ̈n cïnë ke KOBIT-19 yöök ke gup ku a yöök cïït thii kor ë ke gup wɛ̈n cë wïc tɛ̈ɛ̈c.
Women who are pregnant or breastfeeding or who do not have an effective contraceptive method are not eligible.
Diär liɛc wälë thuëëtkï wälë acën dhöl piɛth ye lek röt tit në liɛ̈c ace ke gam.
Several anticoagulants are being tested in Italy.
Antikoagulan kuötic aye ke them Itali
Low-molecular-weight heparin is being widely used to treat patients, prompting the Italian Medicines Agency to publish guidelines on its use.
Heparin nɔŋ athiɛk-ë molekula-tɔ̈ piny aye loi bïnë ayanïn alacu në kuɛr kuötic, en coth en Dutuc ke wɛl ke Itali bïk dhöl e kuany cök në luɔidɛnic piät bec.
A multicenter study on 300 patients researching the use of enoxaparin sodium at prophylaxis and therapeutic dosages was announced in Italy on April 14.
Ɣän kuötic në piööc në baŋ ayanïïn ke 300 yɔ̈ɔ̈pë luɔide enodhaparin thodiööm tënë propailadhïth ku kuɛr ke luɔi de lɔtueŋë pial e cï Itali caal kë Akɔ̈nydït ye nïn 14.
Since SARS-CoV-2 is a virus, considerable scientific attention has been focused on repurposing approved anti-viral drugs that were developed for prior outbreaks such as MERS, SARS, and West Nile virus.
Mënë ye SARS-CoV-2 bairäth, nyïn gäk apɛi e käkë wëi aacï wälë dhuŋe wɛlë bairäth nɔk cï ke gam në luɔndɛnic ɣɔn lui ke MERS, SARS ku wɛ̈th Nail bairäth cë dac lɔbec.
Ribavirin: ribavirin was recommended for COVID-19 treatment according to Chinese 7th edition guidelines
Ribabirin: ribabirin e cï than bïnë KOBIT-19 ya alacu në të cït të cï kuënye cök në agɔ̈t de 7.
Umifenovir: umifenovir was recommended for COVID-19 treatment according to Chinese 7th edition guidelines
Umipenobir: umipenobir e cï than bïnë yïlany de KOBIT-19 ya alacu në të cït të cï kuënyë cök agöt de 7
Some antibiotics that have been identified as potentially repurposable as COVID-19 treatments:
Antibayotik kök cï kuën kë ke lëu bïk dhukë luɔndɛnic ëke yë ya yïlany dë KOBIT-19
Tocilizumab (Anti-IL-6 receptor): Approved by China.
Tocilidhumab (wälde - IL-6 e käŋ titic) cï Caina gam.
Also trials in Italy and China. and see Tocilizumab#COVID-19.
Thëëmthëëm tɔ̈ Itali ku Caina ëyɛ ku tïŋ Tocilithdhumab #KOBIT-19
It is unclear yet whether conditions arising during pregnancy including diabetes, cardiac failure, hypercoagulability or hypertension might represent additional risk factors for pregnant people as they do for nonpregnant people.From the limited data available, vertical transmission during the third trimester probably does not occur, or only occurs very rarely.
Aŋuɔtë kuc apath lɔn ye ɣälɛt röt jat nhial dhamɛn ë liëc nɔŋ yïk thukari, köcë piöu, duötë riɛm wälë puɔrë riɛm aalëu bïk ya kök ë mɛ̈ckëla juak nhom tënë diär liɛc cë mën yenne luɔi tënë kɔc cïï liac. Tënë thönthii dakic tɔ̈, tëëk thïnë tuany në baŋ nhial në kaamë pɛ̈i kediäk kë tɛkdët ka ce rɔtë loi, wälë ace rɔt ë dac loi.
There is no data yet on early pregnancy.
Acën käthii kor tɔ̈ në baŋ de dac liëcic.
Little evidence exists to permit any solid conclusions about the nature of COVID-19 infection in pregnancy.
Këthin ë ye nyuɔth atɔ̈ ago gɛrë wɛ̈t akär la cök puöl në baŋde täde wuɔk ë KOBIT-19.
A case series of 43 women from New York who tested positive for COVID-19 showed similar patterns to non-pregnant adults: 86% had mild disease, 9.3% had severe disease and 4.7% developed critical disease.
Në kä reke cök de tik 43 lɔŋde Niw Yɔk, cï ke yöök ëke nɔŋ tuany de KOBIT-19 e kä thöŋ mat rɔt tënë kɔc ŋuën cïï liɛc. 86% ake nɔŋ tuany piɔlic, 9.3% ake nɔŋ tuany rilic ku 4.7% acë tuany rilic apɛi rɔt loi tënë keek.
Fetal distress was reported in two.
Agänygäny tënë mɛnh liɛc kɔc acï yöök në rouic.
None of the women developed severe COVID-19 pneumonia or died.
Acën tiŋ töŋ e diärkä cï KOBIT-19 alir pi öu nyin dït apɛi tënɔŋyen wälë thou.
All of them had live birth pregnancies and no severe neonatal asphyxia was observed.
keke bën aake nɔŋ liëny dhiëth kek ë mïth kɛn pïr ku cën nëonatal athpidhia cï tïŋ kë rilic.
The samples of breast milk, amniotic fluid, cord blood and neonatal throat swab were tested for SARS-CoV-2, and all results were negative.In another study on 15 pregnant women, majority of the patients presented with fever and cough, while laboratory tests yielded lymphocytopenia in 12 patients.
Ŋuëkthii ë cakë thïn, pïu amniotik, riɛmë cör ku nëonatal alɛnh ë lɔɔk aröölic aake cï ke them në SARS-CoV-2, ku go nëtïja kedhiɛ bën bei kë rɛ̈ɛ̈ric ë pɛth. Në athëëm dët cï luɔi diär kök liɛc ke 15, kɔc juëc ke ayanïïn aacë bënë naŋ atuöc ku ɣɔl, ku go ɣönë thëëm athëëm lɔ nyuɔthë limpothitopenia tënë ayanïïn ke 12.
Computed tomography findings of these patients were consistent with previous reports of non-pregnant patients, consisting of ground-glass opacities at early stage.
Yöök de ayanïïnkä cï cäät në cɔmpiöta aakë tɔ kë cën gɛra kenë guɛl tueŋ cë wɛn ë diär ayanïïn cë liɛc, ke nɔŋic gëlanth piny cenë daithïn në piac jöök.
Follow-up images after delivery showed no progression of pneumonia.Media reports indicate that over 100 women with COVID-19 might have delivered, and in March 2020, no maternal deaths were reported.
Thurɛt de kuënyë cök në thökë dhiëth e ye nyuɔth ë cën lɔtueŋ de tuanyë piöu alir. Cɛɛl/guɛl ë kɔc e cɛɛlë käŋ ayë nyuɔth lɔn cï tik 100 kunhom nɔŋ KOBIT-19 dhiëth ku në Kol 2020, acën thon cï caal tënë dhiëth.
Their guidelines thus advise that any pregnant person admitted to hospital with a COVID-19 infection should receive at least 10 days of prophylactic low-molecular-weight heparin after being discharged from the hospital.
Kuɛrke tiët eke buɔthic e jëëmë lɔn bï gunë raan liac cï tääc panakïm cë wuɔk ë KOBIT-19 alëu bë lööm kä cït nïn ke 10 de propailatik nɔŋ athiɛkde-molekula-tɔ piiny të cïnë ye luöny bei panakïm.
There are no data yet concerning the implications of COVID-19 infections for labour.
Acën käthii kor ë tɔ thiäk kenë wuɔk de KOBIT-19 rilic tënë röp.
One infant girl born to a mother with COVID-19 had elevated IgM levels two hours after birth, suggesting that she had been infected in utero and supporting the possibility of vertical transmission in some cases.
Mɛnh nya ë lual töŋë dhiëth man nɔŋ KOBIT-19 acë kana de IgM jatnyin nhial në thaa kerouic ë dhiëth, ë luel lɔn ë cïnë ye ɣok na dhiëthic ku e ye thanycök en lɔn lëu bï wuök rɔt jɔk nhial ë lɔ piny në kökic.
A small study involving 6 confirmed COVID-19 mothers showed no indication of SARS-COV-19 in their newborns' throats or serum but antibodies were present in neonatal blood sera samples, including IgM in two of the infants.
Akuën thin kor cë apiac dhiëth ke 6 cë yöök ëke nɔŋ KOBIT-19 e nyuɔth lɔn cën en SARS-COV-19 tënë röt ë mïthkɛnthii piɔc dhiëth wälë tuɔk lakin käkë guöp titic aake tɔ tënë ŋuëkthii riɛmë tuɔk ë nëonatal, nɔŋiyïk IgM tënë luët kerou.
This is not usually passed from mother to fetus so further research is required to know whether the virus crossed the placenta or whether placentas of women in the study were damaged or abnormal.
Kënë akën kaŋ tëëk tënɔŋ tik lɔ töŋ meth kë yen yɔɔpdɛt awïc bï nyic lɔn ye bairäth tem lɔŋde lap wälë lɔn cï laap ë diär aa riöök në tïŋdeic wälë cïk tɔ tëden.
Since COVID-19 shows similarities to SARS-CoV and MERS-CoV, it is likely that their effect on pregnancy are similar.
Mënnë ye KOBIT-19 e nyuɔth en thöŋde kekë SARS-CoV ku MERS, alëu bë tɔ bë näk aa thöŋ tënë liëc.
Four of seven had first trimester miscarriage, two of five had fetal growth restriction in the second trimester, and four of five had preterm birth.
Ŋuan në dhorouic aake nɔŋ rɛcë riim në pëi kediäk tueŋ, rou në dhïcic aake ril cilë mïth keke në pëi kediäk de rou, ku ŋuan në dhïcic aake cë thɔrbei.
None of the newborns were infected with SARS-CoV.
Acën töŋ e luëtkä cë wuɔk në SARS-CoV.
A report of ten cases of MERS- CoV infection in pregnancy in Saudi Arabia showed that the clinical presentation is variable, from mild to severe infection.
Guɛl ë käŋke thiär de wuɔkë MERS-CoV tënë liëc lɔŋë Thaudi Arabia e nyuɔth lɔn ye nyothë kïm e rëër kë wääc, në wuɔk kor nyin agut cë wuɔk rilic
The outcome was favorable in a majority of the cases, but the infant death rate was 27%.A recent review suggested that COVID-19 appeared to be less lethal to mothers and infants than SARS and MERS but that there may be an increased risk of preterm birth after 28 weeks' gestation.
Nëtïja e bën bei thïn ee piɛth tënë kä juëc, lakin thonë lual e ye 27%. Adhukë cɛthëic thiök piɔc loië e luel lɔn e KOBIT-19 rɔt nyuɔth kë ye nëk amääth tënë apiac dhiëth ku mïthë luët mënë SARS ku MERS lakin alëu bï naŋ juëkëic ë thörbei batë lätke 28 de liëc.
The World Health Organization and Centers for Disease Control and Prevention of the United States advises pregnant women to do the same things as the general public to avoid infection, such as covering cough, avoid interacting with sick people, cleaning hands with soap and water or sanitizer.
Akutnhom ë Pial Mɛt ë Pinynhom ku Ɣänke tïtë nyin ë Tuany ku Gël tɔ Amërika e diär liɛc jääm nhïïm agokï lui në kë loi juöör ëbën agokï cuɔk wuɔk, cït yïk kumë thok të ɣɔlïn, ba cuök liäp kekë kɔc tuany, wuëk ë cin në athabun ku pïu wälë thënitaidha.
A survey conducted in Shanghai among pregnant women in different trimesters of pregnancy identified a strong demand for online access to health information and services.
Thärbei cï loi në lɔŋde Caŋai tënë diär liɛc në pɛ̈i ë liëc wääc ke diäk acë kuɛnybei lɔn wïcë ɣönlany apɛi ago thön ë pial ku käŋ ya yöök.
People expecting their first baby were more willing to have online consultation and guidance than who had previously given birth.The RCOG and RCM recommend that in-person appointments be deferred by 7 days after the start of symptoms of COVID-19 or 14 days if another person in the household has symptoms.
Kɔc liac në mɛnhdɛn tuɛŋ aakek ëkë anhareic bïk aanaŋ thiëc ɣönlany ku nyuthëke mënë kɔc cë kaŋ dhiëth thɛr. Aye RCOG ku RCM thanpiny lɔn bï yöökë raan ya cuɔt në nïn ka 7 bat cï cïït ë KOBIT-19 jɔk wälë nïn 14 na nɔŋ raandɛt e panëic nɔŋ cïït ëyɛ.
Fever subsequently developed in three asymptomatic patients.
Atuöc acë bënë lɔtueŋ ëtëtöŋë në ayanïï lediäk nɔŋ cïït.
One patient who had tested negative subsequently became symptomatic postpartum and tested positive three days after the initial negative test.
Ayaan töŋ ëcï them go cën kë yöök ye guöp acë bɛ bënë naŋ cïïtë tuany ɛcë dhiëth ku berë yöök kë tɔ ye guöp në thëëm themë ye batë nïn kediäk ke thëëm tueŋ.
The doctors conducting the screening recommended that in order to reduce infection and allocate PPE, due to high numbers of patients presenting as asymptomatic, universal screening of pregnant patients should be conducted.
Dïktoor loi thiëthëic aye kï luel acän ba wuɔk dhuök piny ku wëŋ PPE thok, në wëtë adɛndït tɔ nhial ayanïïn wɛn nyoth cïtë tuany, kë amatnhomde thiëthëic de ayanïïn liɛc bï loi.
They also suggest that people with suspected or confirmed COVID-19 should have continuous electronic fetal monitoring.
Aye kï thɔŋic ë luɛl lɔn bïnë kɔc dɛk kɔc ke piöth wälë cï det ëke nɔŋ KOBIT-19 bïk lɔtueŋ ë mïth liɛcë tït kɔc le nyiin në makana kärba.
The use of birthing pools is not recommended for suspected or confirmed cases of COVID-19 due to the risk of infection via faeces.
luɔide pulë laak akëcë thanpiny tënë kɔc dɛkë piɔth wälë kɔc cï det ëke tuany në KOBIT-19 në wët bïnë wuɔk në ceth.
In the UK, official recommendations state that precautionary separation of a mother and a healthy baby should not be undertaken lightly and that they should be kept together in the postpartum period where neonatal care is not required.Literature from China recommended separation of infected mothers from babies for 14 days.
Thɛnpinydït nyic tɔ UK, aye luel lɔn cë lëu bïnë tïtë nyin tueŋ bïnë mɛnh piɔl guöp atekic kekë man lööm kë piɔlic ku lɔn bïnë ke täu atök në kaam piac dhiëth yenë nëonatal cuökë wïc. Warɛŋë kä cï ke gɔt tɔ Caina aye luel tëkë yic dë amëdhiëëth tënɔŋ mïthkɛn në nïnic ka 14
In the US there is also the recommendation that newborns and mothers should be temporarily separated until transmission-based precautions are discontinued, and that where this is not possible the newborn should be kept 2 metres away from the mother.
Anɔŋ thɛnpinydɛt tɔ US yennë mïthë lual ku märkɛn tekic në kamkoric agut cë tïtë nyin tueŋ ë käke wuɔk temkɔ̈th, ku na e të cë lëuen rɔt thïn kë mɛnhë lual alëu bï täu në mëtïr ke 2 ëmec kekë man.
b'COVID-19 surveillance involves monitoring the spread of the coronavirus disease in order to establish the patterns of disease progression.
Böök ë b'KOBIT-19 anɔŋic tïtë nyin ë lɔ becë tuanyë koronabairäth agorë thurë cäthë lɔtueŋë tuany cɔ̈k piny.
The World Health Organization (WHO) recommends active surveillance, with focus of case finding, testing and contact tracing in all transmission scenarios.
Akutnhom ë Pial Mɛ̈të Pinynhom(APMP) acë böök lui apiɛth thanpiny, kekë rokë nhomthïn në yöökë këdɛ̈, thëmthëm, ku jɔla kuëny cökë käkë yup tënë ɣänë lɔbec ë tuany.
COVID-19 surveillance is expected to monitor epidemiological trends, rapidly detect new cases, and based on this information, provide epidemiological information to conduct risk assessment and guide disease preparedness.
Böök de KOBIT-19 aye ŋɔ̈th bë nyin tït në kä bë bɛ̈n nhial tënë epidɛmiologikol, ku ye kä jöt dac nyic, në kɛnde e thön kënë kɔ̈u, gɛm thönde epidëmiologikal ago mɛ̈ckëla caaric ku böök ajuɛrë tuany.
Syndromic surveillance is done based on the symptoms of an individual that corresponds to COVID-19.
Böökë cïïtë nyin tuany aye loi ë kɛnë cïïtë tuany kɔ̈th raan cë guöp pial në KOBIT-19
As of March 2020, the WHO recommends the following case definitions:
Në Kol ic 2020, kë APMP ecë cɛ̈ɛ̈të kä tɔ̈ cɛ̈ɛ̈nkä thanpiny:
Probable case : "A suspect case for whom testing for the COVID-19 virus is inconclusive" OR "a suspect case for whom testing could not be performed for any reason".
Lëu bë rɔt lëu: "Kë wɛ̈n dekë piɔ̈th na them në KOBIT-19 bairäth, ka cë lëu bë thökde nyuɔth" WÄLË "kë wɛ̈n dekë piɔ̈th na them ka cë lëu bë rɔt loi në wɛ̈të kök".
Confirmed case: "A person with laboratory confirmation of COVID-19 infection, irrespective of clinical signs and symptoms".
Kë cï deet: Raan tɔ̈ ë cë wuɔk në KOBIT-19 cï dët tënë këcïp, acɔkë cën yen kë ye nyuɔth ku cïït ë tuany.
Direct physical contact with a probable or confirmed case;
Gɔ̈të guöp ë raan lëu bë naŋ tuany wälë raan cïï deet kë tuany:
Direct care for a patient with probable or confirmed COVID-19 disease without using proper personal protective equipment;
Tït ë nyin ayan lëu bë tuany wälë cïï deet ke tɔ̈ ke tuany ë KOBIT-19 kë cën kä piɛth ye raan ke rɔt tit.
Other situations as indicated by local risk assessments".WHO recommends reporting of probable and confirmed cases of COVID-19 infection within 48 hours of identification.
Ɣälɛt kök cë mɛn cïnë ye nyuɔth në kɔcthii bai e macakil caathic, "aye APMP thanpiny yennë guelë kä lëu bïk naŋ tuany ku kä cï ke deet ëke cë wuɔk në KOBIT-19 në thaa ke 48 ic ke nyïny cïnë ye nyic."
The countries should report on a case-by-case basis as far as possible, but in case of limitation in resources, aggregate weekly reporting is also possible.
Bɛ̈i apiɛth bïkï ya guɛl në kä loi rɔt në tök-ku-tök të lëu yen rɔt, lakin na nɔŋ të dak lɔŋde käŋ, kë mɛ̈të ic ë läät bï ke jäl caalë tök alëu rɔt.
Some organizations have created crowdsourced apps for syndromic surveillance, where people can report their symptoms to help researchers map areas with concentration of COVID-19 symptoms.
Akutnhïïm kök acë lui në kë ye cïïtë tuany böök tënë dunë kɔc, kë bï kɔc cïïtkɛnë tuany ya luɛl bec thïn ago kɔc yɔ̈ɔ̈p kuɔny klbïk ɣän nɔŋ cïïtë tuany ë KOBIT -19 juëc ya yöök.
Virological surveillance is done by using molecular tests for COVID-19.
Tïtë nyin ë bairäth aye loi në thëëm ë molekular de KOBIT-19.
WHO has published resources for laboratories on how to perform testing for COVID-19.
APMP acë käŋ ɣönë këcïp në të cït të bïnë thëëm de KOBIT-19 ya luɔi thïn.
In the European Union, laboratory confirmed cases of COVID-19 are reported within 24 hours of identification.
Tëde Amɛtnhomde Yuropïn, käke tuany de KOBIT-19 cï ke deet ɣönë këcïp aaye ke caal në thääiyic ka 24 ke nyïny cïnë ye nyic.
At least 24 countries have established digital surveillance of their citizens.
Të cït tënë bɛ̈i ka 24 aakek aacë tïtë nyin në cɔmpiöta cɔ̈k pinytënë mïthkɛnë bai.
The digital surveillance technologies include apps, location data and electronic tags.
Tïtë nyin tɛ̈knɔlojide cɔmpiöta anɔŋic kë yennë lui thïn, thönthii ke tëde rëër ku kä cï ke täu në karba.
The Center For Disease Control and Prevention in USA tracks the travel information of individuals using airline passenger data.
Tëde gëlë riääk ku tïtë nyin tɔ̈ USA, e thönë kɔc caath muök nyin në thönthii ke kɔc caath në riän nhial.
In Hong Kong, authorities are requiring a bracelet and an app for all travellers.
Kɔc akuma de Ɣɔŋ Kɔŋ, awïcë kabeca ku jɔla kë ye käŋ nyuɔth tënë kɔc caath kedhiɛ.
A GPS app is used to track the locations of individuals in South Korea to ensure against quarantine breach, sending alerts to the user and to authorities if people leave designated areas.
GPS e käŋ nyuɔth aaye loi bïnë ɣän ke rëër ë raan aa muök nyin lɔŋde Thauth Koria ago cën dhuŋë löŋde tëuë rɔt tɛ̈n tök kɔ̈u, bë loi ye lɛ̈k ku jɔla kɔc akuma të jɛ̈l kɔc në ɣän cïnë ke täu thïnic.
In Singapore, individuals have to report their locations with photographic proof.
Lɔŋde Thiŋapor, kɔc aaye ɣänkɛn tɔ̈ keke thïn luël kekë thura e ye cäät.
Thailand is using an app and SIM cards for all travelers to enforce their quarantine.
Thailan aloi ke ye käŋ nyuɔth ku SIM tëne kɔc caath kedhiɛ agokï ë cɔke tɔ̈ në ɣänkɛn ë rëër.
Human rights organizations have criticized some of these measures, asking the governments not to use the pandemic as a cover to introduce invasive digital surveillance.
Akutnhïïm tiët nyïn në yinyë kɔc aacë kök e käk jiit cök, e kek akuuma thiëc ëke cë loi ë riäŋ kän kë ke kum bɛ̈i nhial de tïtë nyin rac në cɔmpiöta kɔ̈u.
b'A COVID-19 vaccine is a hypothetical vaccine against coronavirus disease 2019 (COVID-19).
Wäl ë tuöm de KOBIT-19 b'A e wäl ë haipothetikol yennë tuany de Koronabairäth 2019(KOBIT-19) tiɛt wei.
Although no vaccine has completed clinical trials, there are multiple attempts in progress to develop such a vaccine.
Acɔkë cën yen wäl e tuöm cï thääp thëëm në akïm, ka nɔŋ athëëm lɔtueŋ bïk ë wäl ë bëi bei.
In late February 2020, the World Health Organization (WHO) said it did not expect a vaccine against SARS-CoV-2, the causative virus, to become available in less than 18 months.
Në thökë Nyith 2020, kë e cï Akutnhom ë Pial Mɛ̈të Pinynhom(APMP) lueel ke ce ŋɔ̈ɔ̈th bë wäl de SARS-CoV-2, ë ye yenne bairäthë jɔke, bë guɔ ya tɔ̈ ke pɛ̈i ke 18 kën bɛ̈n.
Five vaccine candidates were in Phase I safety studies in April.
Wɛl wɛ̈ɛ̈r kedhïc aake tɔ̈ atëk ë kuën ë pial I në Akɔ̈nydït ic .
COVID-19 was identified in December 2019.
KOBIT-19 ejɔl nyic në Ɣɔ̈r de 2019.
A major outbreak spread around the world in 2020, leading to considerable investment and research activity to develop a vaccine.
Dhoŋ dïtë tuany e jɔl larär ë pinynhom në 2020 ic ago luɔide yɔ̈ɔ̈p cɔkë juak rɔt tëuë käŋ në lɔtueŋic.
Many organizations are using published genomes to develop possible vaccines against SARS-CoV-2.
Akutnhïïm juëc aloi käke jenom cï ke gät bec agokï wɛl ë tiëtë SARS-CoV-2 lëu në luɔi.
Stated in April, imperatives of the CEPI initiative for vaccine development are speed, manufacturing capacity, deployment at scale, and global access.
Në luɛlde në Akɔ̈nydït ic, ajɔkde CEPI në tëude në kɔc nhïïm tëde luɔi ë lɔtueŋ e walë awuur dït apɛi, adɛndɛn ë guërë bec, athëmde luɔide ku jɔla yöök de në pinynhom.
In April, CEPI scientists reported that 10 different technology platforms were under research and development during early 2020 to create an effective vaccine against COVID-19.
Në Akɔ̈nydït ic, MAT de kɔc e lui ë käke wëi aayekï lueel lɔn ye ɣä wääc ke 10 ke tëknɔlojï ake tɔ̈ në yɔ̈ɔ̈p cök ku lɔtueŋ në dhamɛn ajöökë 2020 ago cakë wäl lajik ë KOBIT-19 tit.
Major platform targets advanced into Phase I safety studies include:
ɣänke mahëm cï ke tiëŋ kɔc nyin apɛi aacë ɣet tueŋ në atëk I de kuën piɛth nɔŋic:
nucleic acid (DNA and RNA) (Phase I developer and vaccine candidate: Moderna, mRNA-1273)
Nukëleik athit(DNA) ku RNA(Atëk I de atɛ̈ɛ̈t wäl wëër; Moderna, mRNA-1273)
viral vector (Phase I developer and vaccine candidate: CanSino Biologics, adenovirus type 5 vector)
Bairal bɛkta(Atëkde I atɛ̈t ku wal tɔ̈ känë wɛ̈ɛ̈ric: KanThino Bayologik, nuɔu ë 5 de adenobairäth bɛkta)
As reported by CEPI scientists in April, 115 total vaccine candidates are in early stages of development, with 78 confirmed as active projects (79, according to the Milken Institute), and 37 others announced, but with little public information available (presumed to be in planning or being designed).
Cë mɛnë cïnë ye caal në diktoor ë CEPI në Akɔ̈nydït ic, adɛnë wɛl tɔ̈ në wɛ̈ɛ̈ric ke 115 aatɔ̈ në kanadɛn ajöökic de lɔtueŋë luɔi kekë 78 cï ke deet ke kek ajuɛr loi ëke kek lui thïn(79, në të cït të ye Thukulde Milkën ye luɛl thïn), ku 37 kök cï ke caal, lakin atɔ̈ ke thön kor tënë jäŋ juëc(e thɔ̈ŋic kë tɔ̈ ajuɛric wälë acak).
A Phase I-II trial conducts preliminary safety and immunogenicity testing, is typically randomized, placebo-controlled, and at multiple sites, while determining more precise, effective doses.
Athëm ë I-II de Atëk e piath akërnhiaam loi ku athëm de immunojënithiti aye täu ë cï wɛr, muökë nyinthïn ë plecibo, ku ye tɔ̈ në ɣän kuötic, kë deet kä juëc lacar, dɛ̈k piɛth.
Phase III trials typically involve more participants, including a control group, and test effectiveness of the vaccine to prevent the disease, while monitoring for adverse effects at the optimal dose.
Atëk athëmthëm ë III e naŋ kɔc juëc lui thïn, nɔŋ yïk akuut ë tïtë nyin, ku athëm ë luɔi piɛthë wal ago tuany gël ku yë böökë tïŋ në wɛ̈të mɛ̈ckëla lëu bï loi në dhamɛn dekë ye.
Of 79 vaccine candidates in active development (confirmed as of early April 2020), 74 were not yet in human evaluation (still in "preclinical" research).
Në wɛl tɔ̈ në wɛ̈ɛ̈ric ka 79 kek lui në lɔtueŋic (ëk cï ke deet në ajöök de Akɔ̈nydït 2020), 74 aake ŋot ëke kënë täu në athëm de kɔcic(aŋotë yɔ̈ɔ̈pë yöök ë de ic në akïm).
Around 24 January 2020 in Australia, the University of Queensland announced that it is investigating the potential of a molecular clamp vaccine that would genetically modify viral proteins in order to stimulate an immune reaction.
Në të cït të e Kön nïn 24, 2020 pande Athurelia, jamade Kuinlan e cë caal lɔn kɔr kek piathde molekular wäl cök wɛ̈n lëu bë protin ke bairäth gerë luɔi ku bë käkë guɔ̈p gɛ̈lic në tuany cɔkë lui apiɛth.
Around 24 January 2020 in Canada, the International Vaccine Centre (VIDO-InterVac) at the University of Saskatchewan announced the commencement of work on a vaccine, aiming to start human testing in 2021.
Në të cït të e Kön nïn 24, 2020 pande Kanada, kë Tëde Wal Pinynhom ëbën(VIDO-TeWP) tɔ̈ jamade Thathkat cewan ecë caal yen jɔ̈kë lonë wal, ë ŋɔ̈th bë athëm de raan jɔɔk në 2021 ic.
Vaccine development projects were announced at the Chinese Center for Disease Control and Prevention on 26 January 2020, and the University of Hong Kong on 28 January.
Ajuɛr de lɔtueŋ ë wal e cï Cainïth caal tëdɛnë gëlde tuany ku tïïtë nyinde kë nïnë Kön e 26, 2020, ku jɔla jamade Ɣöŋ Kɔŋ kë Kön e nïn 28.
Around 29 January 2020, Janssen Pharmaceutical Companies, led by Hanneke Schuitemaker, announced that it had begun work on developing a vaccine.
Në të cït të e Kön nïn 29 de 2020, Kɔmpani ɣän wɛl de Janssen, muk Hanneke Schuitemaker, aacë caal lɔn cen luɔi jɔɔk në lɔŋde juɛ̈rë wal.
Janssen is co-developing an oral vaccine with its biotechnology partner, Vaxart.
Janssen e raan töŋë kɔc loi wäl dëk kekë raan de vaxart mët kek tëdɛnë biotechnology.
On 18 March 2020, Emergent BioSolutions announced a manufacturing partnership with Vaxart to develop the vaccine.
Kë Kol e nïn 18, 2020, kë BioSolutions e cë caal lɔn cen mat kekë vaxart tënë guër de wäl.
On 8 February 2020, the laboratory OncoGen in Romania published a paper on the design of a vaccine with similar technology to the one used for cancer neoantigen vaccination therapy.
Kë Nyith e nïn 8, 2020, go ɣönde këcïp de OncoGen tɔ̈ Romania e cë warɛk gät bec në të cït të bï wäl yiën thïn kë thöŋ kekë teknɔloji ɣɔn cï kaŋ loi kë ye neontigen de maguere ye tuɔm bë wɛ̈rë rot tëde tuany ya loi apiɛth.
On 25 March the head of the research institute announced that they had finalized the synthesis of the vaccine and were beginning the tests.
Kë Kol e nïn 25 go madïrde thukul ë yɔ̈ɔ̈p caal lɔn cï kek luɔi ë kä juëcic de wal thääpë luɔi ku aake jɔk athëmthëm.
On 27 February 2020, a Generex subsidiary company, NuGenerex Immuno-Oncology, announced they were beginning a vaccine project to create an Ii-Key peptide vaccine against COVID-19.
Kë Nyith e nïn 27, 2020, go cirga e konyë dhukë pinyde cinë ɣɔ̈c de generex NuGenerex Immuno-onkoloji caal lɔn loi kek ajuɛrde wal ago walë li-key peptite ku bë KOBIT-19 tiɛt wei.
They wanted to produce a vaccine candidate that could be tested in humans "within 90 days."
Ake wïc bïk wal tɔ̈ në wɛ̈ɛ̈ric lëu bï them tënë kɔc bïk loi në "nïnic ke 90".
On 5 March 2020, Washington University in St. Louis announced its projects to develop a vaccine.
Kë Kol e nïn 5 2020, go jaamade Washington tɔ̈ St. Louis e ca ajuɛrden ben wäl loi caal.
On 5 March 2020, the United States Army Medical Research and Materiel Command at Fort Detrick and the Walter Reed Army Institute of Research in Silver Spring, both in western Maryland, announced they were working on a vaccine.
Kë Kol e nïn 5 2020, go Alathkëër de yɔ̈ɔ̈pë wal ka Amërika ku aduɔtka jeec tɔ̈ Fort Detrick ku thukul de Maryland e cɛɛlkï lɔn loi kek wäl.
Around 10 March 2020, Emergent Biosolutions announced that it had teamed with Novavax Inc.
Në të cït të ye Kol nïn 10 2020, e cɛɛl Biosolutions lɔn lui kek atök kenë Novavax Inc.
in the development and manufacture of a vaccine.
në luɔide ku guɛ̈rde wäl.
The partners further announced plans for preclinical testing and a Phase I clinical trial by July 2020.
Kek akutmɛ̈t aake cɛɛl ajuɛr de thëm akërnhiaam de athëmde kïm de atëk I de dïktoor në cït tënë Alɛthbor de 2020.
On 12 March 2020, India's Health Ministry announced they are working with 11 isolates, and that even on a fast track it would take at least around one-and-a-half to two years to develop a vaccine.
Kë Kol e nïn 12, 2020, Wädhärade India de Pial e cë caal lɔn lui kek kenë wëëŋë thok ë 11 ku ë kënë ëyɛ atɔ̈ në kuënyë cökic alëu bï löömë të cït tënë ruön-ku-nhuth agut cë të cït run kerou ku bïï wal jal loi.
On 12 March 2020, Medicago, a biotechnology company in Quebec City, Quebec, reported development of a coronavirus-like particle under partial funding from the Canadian Institutes for Health Research.
Kë Kol e nïn 12 2020, cirga de Biotëknɔloji de Medicago tɔ̈ pande Quebec, ecë luɔi de kä la thueithuei cït-koronabairäth caal ëke ŋuɔtë ke kënë guɔ juir ëbɛ̈n tënë thukuulke Kanada de yɔ̈ɔ̈pë pial.
The vaccine candidate is in laboratory research, with human testing planned for July or August 2020.
Wal tɔ̈ në wɛ̈ɛ̈ric tëde thëm atɔ̈ ɣönde këcïp ë yɔ̈ɔ̈p, kekë athëm tënë kɔc e tɔ̈ në juɛ̈ric bë ya Alɛthbor wälë Aköldït de 2020.
Earlier that week, The Guardian reported that the US President Donald Trump had offered CureVac "'large sums of money' for exclusive access to a Covid-19 vaccine", against which the German government protested.
Në ajɔ e läätë, go Guardian caal lɔn cï bënyë US cɔl Donald Trump e cë CureVac "gäm wëu juëc ago naŋ dhöl piɛth yökë walë Kobit-19" ku yennë kënë acï akumade German bɛ̈në maan.
On 17 March 2020, American pharmaceutical company Pfizer announced a partnership with German company BioNTech to jointly develop a mRNA-based vaccine.
Kë Kol e nïn 17 2020, cirga de Pfizer de ɣönë wɛl Amërika e cë caal lɔn cï kek mat kekë cirga de BioNTech ë Germany ku bïk wäl ë gëlë guöp ë mRNA loi atök.
mRNA-based vaccine candidate BNT162, currently in pre-clinical testing with clinical trials expected to begin in April 2020.
Wäl ë guöp gëlic ë BNT162, atɔ̈ ëmɛn kë them bï yök lɔn yök lɔn bï yen jal lui tënë raan ku athëmde piath lde tënë ayanïïn aye ŋɔ̈th kë jɔk në Alɛthbor de 2020 ic.
In Italy on 17 March 2020, Takis Biotech, an Italian biotech company announced they will have pre-clinical testing results in April 2020 and their final vaccine candidate could begin human testing by fall.
Në Itali kë Kol e nïn 17, 2020, go cirgade Biotech ë kɔc ke Itali e cɔl Takis e cë caal ka bë naŋ nëtïja ë thëm ë wäl kënë guɔ gam ic në Akɔ̈nydït de 2020 ic ku wäldɛn ë guöp gëlic alëu bë thëm jɔɔk tënë raan në dhamɛn mäi ic.
In France on 19 March 2020, the Coalition for Epidemic Preparedness Innovations (CEPI) announced a US$4.9 million investment in a COVID-19 vaccine research consortium involving the Institut Pasteur, Themis Bioscience (Vienna, Austria), and the University of Pittsburgh, bringing CEPI's total investment in COVID-19 vaccine development to US$29 million.
Tënë France kë Kol e nïn 19 2020, go kɔc cë ke cin mat në Ajuɛr ë baŋde Tuany (MAT) caal kë US$4.9 miliöön cï le täuë luɔi de wäl ë gëlë guöp në KOBIT-19 tënë akuut yɔ̈ɔ̈p nɔŋic thukul de Pasteur, Themis Bioscience (Vienna, Austria) ku jaama de Pittsburgh, e bëi ajuɛ̈rë cin de käke luɔi ë KOBIT-19 në të cït tënë miliöön US$29.
CEPI's other investment partners for COVID-19 vaccine development are Moderna, Curevac, Inovio, Novavax, the University of Hong Kong, the University of Oxford, and the University of Queensland.
MAT de Akutnhom ajuɛrdɛ̈t cë ke cin mat në baŋde KOBIT-19 ë luɔi ë wäl ë gëlë guöp aaye Moderna, Curevac, Inovio, Novavax, jaama de Hong Kong, jaama de Oxford ku jɔla jaamde Queensland.
On 20 March 2020, Russian health officials announced that scientists have begun animal testing of six different vaccine candidates.
Në Kol e nïn 20, 2020 ic, bäny ke pial ke Räcca e cïk caal lɔn cï kɔc ë lui ë käk kɔc guup cï kek jɔkë thëm ë läi de wɛlë gëlë guöp wääc.
Imperial College London researchers announced on 20 March 2020 that they are developing a self-amplifying RNA vaccine for COVID-19.
Kɔc ë yɔ̈ɔ̈p tɔ̈ jaama de Imperial tɔ̈ London e cïk caal kë Kol e nïn 20 2020 lɔn loi kek wäl ë gëlë guöp ë RNA e rɔt juak etök kë ye këde KOBIT-19.
The vaccine candidate was developed within 14 days of receiving the sequence from China.
Wäl ë gëlë guöp tɔ̈ në wɛ̈ɛ̈ric ee loi në nïnic ka 14 ke dhamɛn ë löömë kä tɔ̈ në thäpic tënɔŋ Caina.
In late March, the Canadian government announced C$275 million in funding for 96 research projects on medical countermeasures against COVID-19, including numerous vaccine candidates at Canadian companies and universities, such as the Medicago and University of Saskatchewan initiatives.
Në thökde Kol, go akuma ë Kanada caal kë C$275 miliöön cï juar tënë ajuërë yɔ̈ɔ̈p ka 96 në baŋde gɔ̈ɔ̈rë wɛlë KOBIT-19 cök, nɔŋic yïk wɛl juëcë gëlë guöp tɔ̈ në thäpic tënɔŋ cirga de Kanada ku jaamɛt, cït yïk Medicago ku jaama de ajɔkde Saskatchewan.
Around the same time, the Canadian government announced C$192 million specifically for developing a COVID-19 vaccine, with plans to establish a national "vaccine bank" of several new vaccines that could be used if another coronavirus outbreak occurs.
Në ye dhamɛn töŋëic, go akuma ë Kanada caal kë C$192 miliöön ë kë cï ruök luɔi de wäl ë gëlë guöp në KOBIT-19 kekë ajuɛr bï kek "bɛŋë wäl ë gëlë guöp" dɛn bai loi kekë wɛl jöt ë guöp gëlic juëc wɛn lëu bï ke bɛ loi na be naŋ koronabairäth dɛ̈t be rɔt jatnhial.
On 2 April 2020, researchers at the University of Pittsburgh School of Medicine reported on testing of PittCoVacc, a possible COVID-19 vaccine in mice, stating that "MNA delivered SARS-CoV-2 S1 subunit vaccines elicited potent antigen-specific antibody responses [in the mice] that were evident beginning 2 weeks after immunization."
Kë Akɔ̈nydït e nïn 2, 2020, kɔc ë yɔ̈ɔ̈p tɔ̈ Jaama Pittsburgh de thukul ë wɛl e cë thëmde PittCoVacc caal, ëye wäl ë gëlë guöpë KOBIT-19 tënë riëc, ë luel kï lɔn "ye MNA ë SARS-CoV-2 S1 baakic ke wɛlke gëlë guöp cïke gam bec ëke cï juër antigen ril cï ruök käkë guöp gëlic [tënë riëc] ɣɔn cë röt nyuɔth në ajöök läät ka 2 ɛ̈ cï gɛmë wäl jɔɔk."
In Canada on 16 April 2020, the University of Waterloo School of Pharmacy announced design of a DNA-based vaccine candidate as a possible nasal spray.
Lɔŋde Kanada kë Akɔ̈nydït e nïn 16 2020, go jaama ë Waterloo de thukulë ɣönë wɛl caal lɔn cï kek gɔ̈cë wäl ë gëlë guöp tɔ̈ në wɛ̈ɛ̈ric ë DNA kë lëu bë ya kë ye kuɔɔth në umic.
Using bacteriophages, the DNA will be designed to replicate inside human bacteria to produce harmless virus-like particles, which may stimulate the immune system to produce antibodies against the SARS-CoV-2 virus.
Kë ye këde käm ke bairäth e rɔt nuɛt yen bï loi, kë DNA abï loi bë ciët käm tɔ̈ në guöpic ago kä lathueithuei cït-bairäth ce nɛ̈k loi wɛ̈n lëu bë käke guöp titic jɔtnyïïn ago dhiëth në kä tit guöpic tënɔŋ SARS-CoV-2 bairäth
In March 2020, the US government, industry, and three universities pooled resources to access supercomputers from IBM, combined with cloud computing resources from Hewlett Packard Enterprise, Amazon, Microsoft, and Google.
Në Kol ic 2020, go akuma de Amërika, cirga, ku jaama kediäk aake cë käŋ bɛ̈i bɛi bï keke kɔmpiöta dït rilë caathic tënë IBM, ë cï mat kekë käke kɔmpiöta tënë Hewlett Packard Enterprisen, Amazon, Microsoft ku jɔla Google
Some vaccines have heterologous effects, also called non-specific effects.
Wɛlë tiëtë guöp kök anɔŋ macakël kuötic, aaye ke cɔl kä cën macakël cï rok ëya.
That means they can have benefits beyond the disease they prevent.
Yennë kënë aye nyuɔth ka nɔŋ riba yëkïk yök wär tuany gëlkï.
A further randomized trial in Australia is seeking to enrol 4,170 healthcare workers.
Athëmdɛ̈t cï wɛr bec Athurelia awïc bë dïktoor ka 4,170 luöi.
It is possible vaccines in development will not be safe or effective.
Alëu rot wal tɔ̈ në luɔiic acë bë piath wälë lui.
Early research to assess vaccine efficacy using COVID-19-specific animal models, such as ACE2-transgenic mice, other laboratory animals, and non-human primates, indicate a need for biosafety-level 3 containment measures for handling live viruses, and international coordination to ensure standardized safety procedures.
Yɔ̈ɔ̈p cï dac loi në görë luɔi lajik ë wal kë yë loi në kä cï ruök KOBIT-19 në baŋde läi, cït yïk ACE2-riɛ̈c cïnë kë genom kɛn liäp kë genom ë kök, läi kök de ɣön këcïp, ku läi cën cëëkë kɔc, aye nyuɔth lɔn wïcë biosafety-kana de 3 ë mënyde bairäth pïr ku jɔla juir dït de pinynhom agorë dhilë nyic lɔn cïnë dhöl ë pial cɔ̈k.
Vaccines against SARS and MERS have been tested in non-human animal models.
Wɛlke SARS ku MERS aacï ke them tënë läi cën ciɛ̈kë kɔc.
As of 2020, there is no cure or protective vaccine for SARS that has been shown to be both safe and effective in humans.
Mɛ̈në 2020, acën walë yïlac wälë gël ë SARS cï nyuɔth kë lëu bï piath ku lui tënë kɔc.
According to research papers published in 2005 and 2006, the identification and development of novel vaccines and medicines to treat SARS was a priority for governments and public health agencies around the world.There is also no proven vaccine against MERS.
Në të cït të ye warɛk kë yɔ̈ɔ̈p ɣɔn cï gät bec dhamɛn 2005 ku 2006, nyuöthde ku luɔi de wɛl ë gël guöp ku wɛl ke yilac bïnë ke yïlɛnyë SARS e yene ketueeŋ ë tɔ̈ akuuma nhïm ku jɔla dutuuc ke pialë juɔr në pinynhom. Ayɛ acën wal ëtuöm ë guöp gëlicnë MERS cï yök.
When MERS became prevalent, it was believed that existing SARS research may provide a useful template for developing vaccines and therapeutics against a MERS-CoV infection.
Mënë le MERS thiäi pinynhom, eye yök akutnhom ë yɔ̈ɔ̈p de SARS tɔ̈ ëmɛnë ka lëu bïk naŋ kë de luɔi lui apiɛth gam në baŋ de luɔi ë wɛlë tuömë gëlë guöp ku käkë guöp waric wuɔkë MERS-CoV.
As of March 2020, there was one (DNA based) MERS vaccine which completed phase I clinical trials in humans, and three others in progress, all of which are viral-vectored vaccines, two adenoviral-vectored (ChAdOx1-MERS, BVRS-GamVac), and one MVA-vectored (MVA-MERS-S).
Mënë Kol 2020, e nɔŋ töŋë (kënë DNA) walë gël MERS cë atëk ë thëëm ë I thääp thok tënë kɔc, ku kök ke diäk lɔtueŋ ëmɛn, keek ëbɛ̈n aaye wɛlke bairäth-cï rok, rou ëke adenobairäth- cï rok(ChAdOx1-MERS, BVRS-GamVac), ku töŋë MVA-cï rok(MVA-MERS-S).
Social media posts have promoted a conspiracy theory claiming the virus behind COVID-19 was known and that a vaccine was already available.
Kä ye kɔc ke intërnɛt gät bec acë kë ye lueel wa bairäthë cɔk KOBIT-19 ca bɔ ka nyic ku walë gëlde atɔ̈.
The patents cited by various social media posts reference existing patents for genetic sequences and vaccines for other strains of coronavirus such as the SARS coronavirus.
Ayanïn cï kɔc juëc ke intërnɛt luɛl bec në gɔ̈tdenic e ayanïn tɔ̈ ëke nɔŋ cäät ëtɔ̈ keke në guöpdenic e yë cök kuany ku wɛlë gël ëkä rilic ke koronabairäth kök cït yïk koronabairäth de SARS.
b'Coronaviruses are a group of related viruses that cause diseases in mammals and birds.
b'Koronabairäth aye akuutë bairäth thiäkic wɛ̈n e tuenytueny loi tënë läi ku diɛt.
In humans, coronaviruses cause respiratory tract infections that can range from mild to lethal.
Tënë kɔc, koronabairäth e të ye alir ë tëëk thïn wuɔɔkic wɛ̈n lëu bï jɔɔk kë kor agut cë kë nɛ̈k.
Mild illnesses include some cases of the common cold (which has other possible causes, predominantly rhinoviruses), while more lethal varieties can cause SARS, MERS, and COVID-19.
Tuany kor anɔŋ yïk käke athiɛkë nhom(ku e naŋ kökë ëye jɔɔk, bariräth kë thonythony e dhiac ke tɔ̈), kë kä kuötic nɛ̈k apɛi alëu bïkë SARS, MERS, ku jɔla KOBIT-19 jɔk.
Symptoms in other species vary: in chickens, they cause an upper respiratory tract disease, while in cows and pigs they cause diarrhea.
Cïït tënë läi kök aayic wööc: tënë ajïïth, aaye tuanyë të ye alir tëëk jɔɔk, ku tënë ɣɔ̈k ku kadhuruk aaye yäc jɔɔk.
There are yet to be vaccines or antiviral drugs to prevent or treat human coronavirus infections.
Wɛlke gëlë guöp ku wɛlë bairäth tit aŋot e gël wälë lui raann alɛcu në wɔɔkë koronabairäth